Why the study?
Identifying strategies to reduce atrial high-rate episodes is clinically relevant, and the potential role of SGLT2 inhibitors in subclinical atrial arrhythmias remains to be clarified.
Does SGLT2i use reduce the occurrence of atrial high-rate episodes in adult patients with cardiac implantable electronic devices?
Population
123 patients with CIEDs
Comparison
SGLT2i users vs nonusers
Design
Retrospective cohort study
Key result
SGLT2i use was associated with a 68% lower risk of atrial high-rate episodes compared to nonusers in patients with cardiac implantable electronic devices (HR 0.32).
Authors
Loading...
May support SGLT2i antiarrhythmic effects in CIED patients; extends known benefits but is hypothesis-generating pending RCTs.
Cohort (n=123)
No
Does SGLT2i use reduce the occurrence of atrial high-rate episodes in adult patients with cardiac implantable electronic devices?
Effect estimate: HR 0.32 (95% CI 0.10-0.98)
Absolute Event Rate: 40.76% vs 1304.97%
p-value: p=0.03
In patients with cardiac implantable electronic devices, SGLT2i use was associated with a 68% reduction in the risk of subclinical atrial high-rate episodes, suggesting a potential novel antiarrhythmic benefit.
Thirakraisri et al. (2026) conducted a cohort in Cardiac Implantable Electronic Devices (CIEDs) (n=123). Sodium-glucose cotransporter-2 inhibitors (SGLT2i) vs. Non-SGLT2i users was evaluated on Occurrence of Atrial High-Rate Episodes (AHREs) (HR 0.32, 95% CI 0.10-0.98, p=0.03). SGLT2i use was associated with a 68% lower risk of atrial high-rate episodes compared to nonusers in patients with cardiac implantable electronic devices (HR 0.32).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: